Vivendi SA (VIV)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 1.550 |
|---|---|
| 52-week range | 1.397 – 3.212 |
| Return, 1 month / 3 months | +5.2% / −17.2% |
| Return, 1 year / 3 years | −50.2% / −80.4% |
| Trend | Below its 200-day average |
| RSI (14) | 55 |
| Volatility (1 year) | 41.7% |
| Worst drawdown (1 year) | -54.0% |
| Average daily value traded | 3.57M EUR |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vivendi is a French media and entertainment group based in Paris. Its businesses span television, film, publishing, advertising and communications, with pay-television and content production through Canal+ among its main activities. It serves audiences and advertisers across France and other European markets, and it has held interests in music, book publishing and video games. The group operates as a holding company overseeing these media and content businesses.
On this site Vivendi SA appears as a stock on the Euronext Paris (France), code VIV, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vivendi SA (VIV) trades on the Euronext Paris in France. It last closed at EUR 1.550 on 23 October 2026.
Its price-based Market X-Ray is 37 out of 100 (a weak price profile), ranking 462 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 50.2% and over the last three months it fell 17.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 21 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -20.0% | ||
| From 52-week high | -51.1% | ||
| Momentum | 21 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -17.2% | ||
| 6-month return | -28.5% | ||
| 12-month return, skipping the last month | -52.7% | ||
| Stability (higher is calmer) | 37 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -54.0% | ||
| Liquidity | 86 · Strong | Trades actively. | |
| Average daily value traded | 3.57M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −1.1% |
|---|---|
| 1 month | +5.2% |
| 3 months | −17.2% |
| 6 months | −28.5% |
| 1 year | −50.2% |
| 3 years | −80.4% |
| 5 years | −84.9% |
Signals
| 50-day / 200-day average | 1.533 / 1.937 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.044 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Apr 2026 | EUR 0.0400 |
| 29 Apr 2025 | EUR 0.0400 |
| 16 Dec 2024 | EUR 6.4874 |
| 30 Apr 2024 | EUR 0.2500 |
| 25 Apr 2023 | EUR 0.2500 |
| 26 Apr 2022 | EUR 0.2500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.